Latest News
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
25 March 2026 - Dutch health technology company Royal Philips (NYSE:PHG) (AEX:PHIA) on Wednesday introduced IntraSight Plus, an interventional cardiology platform cleared for clinical use in the United States and Europe, combining diagnostic and trea...
Bio-Techne expands COMET spatial biology platform with new SPYRE Panels and Amplification Kits
25 March 2026 - Bio-Techne Corporation (NASDAQ: TECH) announced on Wednesday that it has expanded its COMET spatial biology portfolio with the introduction of SPYRE Focus Panels and SPYRE Amplification Kits, enhancing flexibility and sensitivity acro...
CRISM Therapeutics advances Phase 2 glioblastoma trial with initial ChemoSeed batch manufactured
25 March 2026 - UK clinical-stage drug delivery company CRISM Therapeutics Corporation (AIM: CRTX) on Wednesday reported progress in its Phase 2 clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma, confirming the successful manuf...
Myosin Therapeutics granted USD2m funding from Florida Department of Health
25 March 2026 - Myosin Therapeutics, a Florida-based biotechnology company, announced on Tuesday that it has been awarded USD2m in funding from the Florida Department of Health through the Casey DeSantis Florida Cancer Innovation Fund (FCIF).This fun...
Clover Biopharmaceuticals reports positive US Phase I data for RSV re-vaccination in older adults
25 March 2026 - Commercial-stage biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) on Tuesday reported additional positive data from a Phase I clinical trial in the United States evaluating re-vaccination with the company's RSV Pr...